Opsonic activity of commercially available standard intravenous immunoglobulin preparations.
Several standard intravenous immunoglobulin G (IVIG) products are available in the United States and have been used with the intent to treat or prevent infections in neonates. We evaluated more than 100 lots of IVIG, from 6 products, to determine the amount of opsonic antibody against neonatal pathogens. Neutrophil-mediated opsonophagocytosis was used to determine opsonic activity in these preparations for Staphylococcus epidermidis; Haemophilus influenzae type b; Streptococcus pneumoniae serotypes 3, 14 and 19; Group B Streptococcus serotypes Ia, Ib, Ia/c, II and III; and Escherichia coli (K1). Pathogen-specific opsonic activity of the lots tested ranged from undetectable to 1:80 and was detectable in < 10% to > 90% of lots tested depending on the organism and manufacturer. Within an IVIG lot there was variable opsonic activity against different strains or serotypes of the same organism. Opsonic activity was significantly (P < or = 0.05) affected by the manufacturer's donor pool and less so by the manufacturing method. We conclude that the pathogen-specific opsonic antibody activity of an IVIG lot is: (1) highly variable for several common neonatal pathogens; (2) predominantly dependent on the donor pool and not the manufacturing method. Clinicians may more appropriately select therapy if the pathogen-specific antibody content of IVIG products by lot are known. In the future neonatal IVIG research should focus on using preparations with known pathogen-specific antibody activity.
Weisman
L E
LE
Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD.
Cruess
D F
DF
Fischer
G W
GW
D000704:Analysis of Variance; D015169:Colony Count, Microbial; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D004926:Escherichia coli / Q000187:drug effects*; D006193:Haemophilus influenzae / Q000187:drug effects*; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000592:standards; D009895:Opsonin Proteins / Q000187:drug effects*; D010587:Phagocytosis / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*; D013292:Streptococcus agalactiae / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects; D014481:United States
D016756:Immunoglobulins, Intravenous; D009895:Opsonin Proteins